The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism

Archives of Internal Medicine

Volumn 162, Issue 20, 2002, Pages 2357-2360

  Eichinger, Sabine ^a   Weltermann, Ansgar ^a   Mannhalter, Christine ^a   Minar, Erich ^a   Bialonczyk, Christine ^c   Hirschl, Mirko ^d   Schönauer, Verena ^a   Lechner, Klaus ^a   Kyrle, Paul A ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c WILHELMINEN HOSPITAL   (Austria)

^d HANUSCH HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; LUPUS ANTICOAGULANT;

ANTICOAGULATION; ARTICLE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SEX RATIO; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADULT; AGED; COHORT STUDIES; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; RECURRENCE; RISK ASSESSMENT; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0037111813     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.20.2357     Document Type: Article

References (28)

1. Federman DG, Kirsner RS. An update on hypercoagulable disorders. Arch Intern Med. 2001;161:1051-1056.
2. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95:1517-1532.
3. Svensson PJ, Dahlbäk B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
4. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-1506.
5. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood. 1993;82:1989-1893.
6. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
7. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2802.
8. Simioni P, Prandoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism in patients with an Arg50CGln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399-403.
9. Simioni P, Prandoni P, Lensing AWA, et al. Risk of subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood. 2000;96:3329-3333.
10. Rintelen C, Pabinger I, Köbl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost. 1996;75:229-232.
11. Eichinger S, Pabinger I, Stümpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997;77:624-628.
12. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the 620210A allele in the prothrombin gene: DURAC Trial Study Group. Thromb Haemost 1999;81:84-89.
13. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
14. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999;341:801-806.
15. Margaglione M, D'Andrea G, Colaizzo D, et al. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost. 1999;82:1583-1587.
16. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. JAMA. 1990;263:2753-2759.
17. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
18. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene. Blood. 1996;88:3698-3703.
19. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457-462.
20. Brandt JT, Triplett DA, Alving B, Scharrer I, for the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemost. 1995;74:1185-1190.
21. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost. 2001;86:395-403.
24. Eichinger S, Stümpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost. 1998;80:566-569.
25. Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14-17.
26. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332:1661-1665.
27. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anti-coagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep-vein thrombosis. Circulation. 2001;103:2453-2460.
28. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med. 2001;345:165-169.